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Abstract
Although the relationship between positive and negative symptoms of psychosis and dyslipidemia has been thoroughly inves-
tigated in recent studies, the potential link between depression and lipid status is still under-investigated. We here examined 
the association between lipid levels and depressive symptomatology in patients with psychotic disorders, in addition to their 
possible inflammatory associations. Participants (n = 652) with the following distribution: schizophrenia, schizophreniform 
and schizoaffective disorder (schizophrenia group, n = 344); bipolar I, II, NOS, and psychosis NOS (non-schizophrenia group, 
n = 308) were recruited consecutively from the Norwegian Thematically Organized Psychosis (TOP) Study. Clinical data 
were obtained by Positive and Negative Syndrome Scale (PANSS), and Calgary Depression Scale for Schizophrenia (CDSS). 
Blood samples were analyzed for total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), C-reactive protein 
(CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), and interleukin 1 receptor antagonist 
(IL-1Ra). After adjusting for age, gender, BMI, smoking, and dyslipidemia-inducing antipsychotics, TC and LDL scores 
showed significant associations with depression [β = 0.13, p = 0.007; β = 0.14, p = 0.007], and with two inflammatory mark-
ers: CRP [β = 0.14, p = 0.007; β = 0.16, p = 0.007] and OPG [β = 0.14, p = 0.007; β = 0.11, p = 0.007]. Total model variance 
was 17% for both analyses [F(12, 433) = 8.42, p < 0.001; F(12, 433) = 8.64, p < 0.001]. Current findings highlight a potential 
independent role of depression and inflammatory markers, CRP and OPG in specific, in the pathophysiology of dyslipidemia 
in psychotic disorders.
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Introduction
Patients with schizophrenia and other psychotic disorders 
tend to have higher serum lipid levels than the general popu-
lation [1]. The well-documented metabolic adverse effects 
of antipsychotics, together with unhealthy lifestyle that 
includes smoking and poor dietary habits, aggravate this 
phenomenon, affect the overall prognosis and could increase 
the risk of premature death in this group of patients [2, 3].
Alteration in lipid levels has been found not only in 
medicated, chronic patients, but also in drug-naive patients 
with first-episode psychosis, as demonstrated in a recent 
meta-analysis comprising 19 studies which revealed higher 
levels of triglycerides (TG) and lower levels of total cho-
lesterol (TC) in patients compared to healthy controls [4]. 
The baseline dyslipidemia found in this study, in addi-
tion to the shared genetic overlap between schizophrenia 
and cardio-metabolic risk factors found in genome-wide 
association studies (GWASs), especially the loci related to 
triglyceride, low- and high-density lipoproteins cholesterol 
(mainly loci on gene regions: TCF4, TRIM26, MAD1L1 
and MMP16) gives rise to the possibility of a disease-
specific lipid pathway underlying the pathophysiology of 
psychotic disorders [5].
On the other hand, the relation between lipid disturbances 
and clinical characteristics of psychotic disorders is still not 
well understood, mainly due to fluctuation of symptoms 
severity as the disease progress and the presence of multiple 
factors that affect lipid levels. The findings of a recent 5-year 
follow-up study about the associations between higher lipids 
levels, severity of psychotic symptoms and level of func-
tioning support the idea that raised lipid levels could be a 
disease trait in schizophrenia [6]. However, it is not clear if 
this association is specific to schizophrenia, and whether it is 
related to specific clusters of symptoms or symptom domain, 
i.e. only positive and negative symptoms or if it could be 
also related to depressive symptoms.
A relation between depression and lipid disturbances has 
been demonstrated in a substantial body of research [7–9], 
and depressed patients are also found to be at higher risk of 
developing cardiovascular diseases [10]. In addition, a recent 
study demonstrated that high levels of TC, LDL, TG, glu-
cose and low level of HDL are present across schizophrenia, 
bipolar and unipolar mood disorders [11]. Another follow-
up study of first-episode psychosis patients demonstrated 
an association between increased high-density lipoprotein 
(HDL) and reduced negative symptoms after 1 year of treat-
ment with antipsychotic medications [12]. Although there 
are indications that dyslipidemia is associated with increased 
severity of psychotic symptoms, and possibly associated also 
with depressive symptoms in the spectrum of psychotic dis-
orders, this has previously not been studied in detail.
In addition, large body of research suggests that inflam-
mation and immune dysfunction might have a potential role 
in the pathophysiology of schizophrenia [13, 14], depres-
sion [15] and dyslipidemia [16]. Moreover, inflammation has 
been suggested to be the underlying mechanism that links 
depression and metabolic syndrome [17, 18]. In earlier study, 
a set of inflammatory cytokines hase been investigated in 
patients with psychotic spectrum disorders including inter-
leukin 1 receptor antagonist (IL-1Ra), soluble tumor necro-
sis factor receptor 1 (sTNF-R1), osteoprotegerin (OPG), and 
von Willebrand factor (vWf) [13]. Being a soluble mem-
ber of the superfamily of TNF-R, osteoprotegerin (OPG) is 
currently considered a potential marker that is involved in 
both cardiovascular diseases [19] and severe mental disor-
ders by several hypothesized mechanisms mainly related to 
inflammation and calcium homeostasis [20]. There is thus 
an increased need to investigate its role in depression and 
lipid dysfunction within psychotic disorders.
The primary aim of the current study is to investigate 
the association between serum lipid levels (total cholesterol, 
LDL and triglycerides) and depressive symptoms in a large 
clinical sample of patients with psychotic disorders; more 
specifically to investigate if higher levels of serum lipids are 
associated with higher levels of depressive symptoms. A 
secondary aim is to assess the possible clinical and inflam-
matory associations to dyslipidemia.
Methods
Subjects were recruited consecutively as part of the Themat-
ically Organized Psychosis (TOP) Study between 2003 and 
2015 from psychiatric departments of five major hospitals in 
the catchment areas of greater Oslo, Norway. The study was 
approved by the Regional Committee for Medical Research 
Ethics. After providing a written informed consent, partici-
pants were assessed with comprehensive clinical and bio-
chemical assessments. Inclusion criteria for the TOP study 
are: age between 18 and 65 years and having a diagnosis 
of psychotic disorder within the schizophrenia and bipolar 
spectrum disorders according to DSM-IV. Participants with 
mental retardation, significant head injury, neurological dis-
order, or autoimmune disease were excluded from the study. 
More details about the TOP study are described in [21, 22].
Participants
For the current study, we included subjects with one or more 
psychotic episodes and available serum lipid measurements. 
We excluded patients with CRP above 10 mg/L (n = 44) and 
patients with missing clinical, lipid or inflammatory data at 
time of recruitment, which are related to the main research 
question of the study. The final sample consisted of 652 
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participants with the following distribution of diagnoses: 
schizophrenia group (n = 344) which includes schizophrenia 
(n = 247), schizophreniform (n = 36) and schizoaffective dis-
order (n = 61); and non-schizophrenia group (n = 308) which 
includes bipolar I (n = 126), bipolar II (n = 58), bipolar NOS 
(n = 10), and psychosis NOS (n = 114).
Procedures
Clinical variables
Demographic and clinical data were obtained by clinical 
interviews and from medical records. Diagnosis was estab-
lished by use of the Structured Clinical Interview for DSM-
IV Axis I Disorders (SCID-I) [23]. Current symptomatol-
ogy was assessed by the following scales: the Structured 
Interview for the Positive and Negative Syndrome Scale 
(PANSS) [24]. The Calgary Depression Scale for Schizo-
phrenia (CDSS) was used to assess depressive symptoms in 
patients with psychosis apart from negative and extrapyrami-
dal symptoms [25]. We calculated duration of illness using 
the age at time of the study inclusion minus age of onset 
of first psychotic, manic, hypomanic or depressive episode. 
Standardized procedures were conducted in physical exami-
nation including height, weight and body mass index (BMI) 
together with a routine checkup by a physician to exclude 
any signs of ongoing infections.
Biochemical variables
Fasting venous blood samples were obtained in the morning. 
Serum lipids, i.e. total cholesterol (TC), triglyceride (TG) 
and low-density lipoproteins (LDL) were measured and ana-
lyzed according to standard techniques at the Department of 
Clinical Biochemistry, Oslo University Hospital. We added 
to the analysis a selected set of robust inflammatory markers, 
i.e. C-reactive protein (CRP), soluble tumor necrosis factor 
receptor 1 (sTNF-R1), osteoprotegerin (OPG) and interleu-
kin-1 receptor antagonist (IL-1Ra) which have a potential 
role in psychosis pathophysiology [13, 26, 27].
Psychotropic medications
Pharmacological treatment may affect lipid levels as 
reported in many studies [28, 29]. We retrieved medication 
data from medical records, clinical interviews and measure-
ments of antipsychotic drugs in serum of the participants 
to assess the degree of regularity of medications. Then, we 
categorized them into two subgroups according to their level 
of dyslipidemic effects (i.e. clozapine/olanzapine group vs 
other antipsychotics) [30].
Statistical analysis
The data were treated using the Statistical Package for Social 
Sciences (IBM SPSS Statistics v. 24) (SPSS Inc., Chicago, 
IL, USA/IBM, New York, USA). The level of statistical sig-
nificance was preset to p < 0.05 (two tailed). Variables were 
presented as percentage and mean (± standard deviation) 
as appropriate. t test and the Chi-square test were used for 
comparisons between schizophrenia and non-schizophrenia 
groups regarding sociodemographic, clinical and biochemi-
cal variables (Table 1). One-way between-group analysis 
of covariance (ANCOVA) was added to assess the effect 
of putative confounders on serum lipid levels. Covariates 
were a priori selected on the basis of previously reported 
associations with lipids, in addition to variables that showed 
significant bivariate association with lipid levels in our sam-
ple analysis (Fig. 1).
To investigate the association between symptom pro-
files, lipid levels and inflammatory markers, we explored 
their bivariate association using Pearson’s r for normally 
distributed continuous variables as shown in Table 2. To 
investigate the possible risk factors for hyperlipidemia, we 
conducted a hierarchal block-wise multiple linear regression 
analysis. TC and LDL were entered in two separate analyses 
as the dependent (outcome) variables with symptom profiles 
(positive, negative and depression) as independent variables 
in the first block. In the second block, we entered variables 
that showed associations with both TC and LDL in the 
bivariate analyses, i.e. age, gender, BMI, smoking, duration 
of illness, diagnostic categories and antipsychotics. In the 
third and final block, we entered inflammatory markers that 
showed significant correlation with TC and LDL, i.e. CRP 
and OPG. The residual plots showed satisfactory model fits 
and the analyses are shown in Table 3.
Results
Description of the participants and group comparison 
between the schizophrenia and non-schizophrenia groups are 
summarized in Table 1. The depression scores in the schizo-
phrenia group were not statistically different from the non-
schizophrenia group (6.36 ± 4.45 compared to 6.11 ± 4.43, 
respectively) (t = 0.73, p = 0.468). In addition, there was 
no statistically significant difference between the groups 
regarding BMI, with slightly higher values in schizophre-
nia (25.54 ± 4.90) than non-schizophrenia (25.47 ± 4.45). 
In contrast, the schizophrenia group had higher levels of 
TC (t = 2.10, p = 0.036), LDL (t = 2.59, p = 0.010) and TG 
(t = 2.90, p = 0.004) compared to non-schizophrenia. These 
higher levels remained significant for TC and LDL after 
adjustment for age, gender, BMI, smoking, duration of ill-
ness, and medications as shown in Fig. 1.
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In the bivariate analyses, we found high levels of TC and 
LDL to be significantly associated with depressive symp-
toms (r = 0.11, p = 0.007; r = 0.11, p = 0.004), whereas high 
levels of TG and LDL were significantly correlated with 
negative symptoms (r = 0.15, p < 0.001; r = 0.10, p = 0.009). 
There were no significant bivariate correlations between 
lipid levels and positive symptoms. CRP showed signifi-
cant positive correlation with lipid levels; TC (r = 0.23, 
p < 0.001), LDL (r = 0.26, p < 0.001) and TG (r = 0.26, 
p < 0.001). In addition, OPG was significantly correlated 
with TC (r = 0.19, p < 0.001) and LDL (r = 0.13, p = 0.005). 
While sTNFR1 showed significant positive association only 
with TG (r = 0.10, p = 0.040). Other correlations between 
lipid levels and inflammatory markers did not reach statisti-
cal significance (Table 2).
In the regression analyses, depression severity as meas-
ured by CDSS appeared to be the sole clinical symptom 
domain associated with high levels of both TC and LDL. 
After multivariate adjustment for age, gender, BMI, smok-
ing, duration of illness, diagnostic categories and use of 
dyslipidemia-related antipsychotic medication (i.e. clozap-
ine and olanzapine), the CDSS score remained significantly 
associated with high TC (β = 0.13, p = 0.007) and LDL 
(β = 0.14, p = 0.007) levels. Other significant associations 
of high LDL levels were higher age (β = 0.25, p < 0.001) 
and BMI (β = 0.11, p = 0.027), whereas female gender was 
associated with lower LDL levels (β = − 0.16, p = 0.001). 
Moreover, both CRP and OPG were found to be signifi-
cantly associated with increased levels of TC and LDL. 
The total variance explained by the model for both TC and 
Table 1  Subject characteristics in schizophrenia and non-schizophrenia groups
M mean, SD standard deviation, t Student’s t test, χ2 Chi-square test, PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression 
Scale for Schizophrenia, BMI body mass index, TC total cholesterol, LDL low-density lipoprotein, TG triglyceride, CRP C-reactive protein, 
sTNF-R1 soluble tumor necrosis factor receptor 1, OPG osteoprotegerin, IL-1Ra interleukin 1 receptor antagonist
*p < 0.05, **p < 0.01
Schizophrenia n = 344 Non-schizophrenia n = 308 Statistics
Age (years), M (SD) 28.67 (8.82) 31.33 (10.70) t = − 3.44**
Female gender, n (%) 148 (43) 168 (54.5) χ2 = 8.64**
Education (years), M (SD) 12.95 (2.82) 14.16 (2.87) t = − 5.44**
Caucasian ethnicity, n (%) 269 (78.2) 261 (84.7) χ2 = 4.57*
Daily smoking, n (%) 202 (58.7) 155 (50.3) χ2 = 4.62*
Duration of illness (years), M (SD) 5.61 (6.63) 7.28 (8.56) t = −  2.77**
Psychotropic medications
 Use on regular basis, n (%) 303 (88.1) 240 (77.9) χ2 = 12.05**
 Antipsychotics inducing dyslipidemia, n (%) 131 (38.1) 67 (21.8) χ2 = 20.50**
PANSS positive, M (SD) 15.84 (5.41) 11.46 (4.09) t = 11.73**
PANSS negative, M (SD) 16.34 (6.14) 11.32 (4.50) t = 11.98**
CDSS, M (SD) 6.36 (4.45) 6.11 (4.43) t = 0.73
BMI (kg/m2), M (SD) 25.54 (4.90) 25.47 (4.45) t = 0.19
TC (mmol/L), M (SD) 5.10 (1.03) 4.93 (1.02) t = 2.10*
LDL (mmol/L), M (SD) 3.18 (0.95) 2.99 (0.88) t = 2.59**
TG (mmol/L), M (SD) 1.41 (0.87) 1.24 (0.65) t = 2.90**
CRP (mg/L), M (SD) (n = 446) 3.04 (2.61) 2.79 (2.48) t = 1.04
sTNF-R1 (ng/mL), M (SD) (n = 441) 1.88 (0.71) 1.85 (0.68) t = 0.49
OPG (ng/mL), M (SD) (n = 446) 1.33 (0.40) 1.34 (0.42) t = − 0.60
































Fig. 1  Marginal means in (mmol/L) of total cholesterol (TC), low-
density lipoprotein (LDL) and triglyceride (TG) in schizophrenia and 
non-schizophrenia groups after adjusting for age, sex, BMI, smoking, 
duration of illness and the use of antipsychotics inducing dyslipi-
demia. *p < 0.05
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LDL analyses was 17% [F(12, 433) = 8.42, p < 0.001; F(12, 
433) = 8.64, p < 0.001] as shown in Table 3.
Discussion
We here demonstrate that high levels of TC and LDL were 
positively associated with depression in patients with psy-
chotic disorders. This association remained significant after 
adjusting for potential confounding factors, including BMI, 
smoking status and use of dyslipidemia-related antipsy-
chotic medications. Mean depressive symptoms scores in 
both the schizophrenia and non-schizophrenia groups were 
just around the cutoff score of 6 points of CDSS, which 
has been considered to identify depression in patients with 
schizophrenia [31]. Although depression means were not 
uniformly high, this does not exclude the potential negative 
impact of depression even on subsyndromal level on quality 
of life, level of functioning, degree of distress and medical 
comorbidity as reported in several studies [32–34].
Table 2  Correlation between symptom profiles, serum lipid levels and inflammatory markers
Bivariate associations were investigated using Pearson’s r correlation coefficient
*p < 0.05, **p < 0.01
TC total cholesterol, LDL low-density lipoprotein, TG triglyceride, CRP C-reactive protein, sTNF-R1 soluble tumor necrosis factor receptor 1, 
OPG osteoprotegerin, IL-1Ra interleukin 1 receptor antagonist
PANSS positive PANSS negative CDSS TC LDL TG CRP OPG sTNFR1
TC (n = 652) 0.05 0.07 0.11** 1
LDL (n = 652) 0.08 0.10** 0.11** 0.92** 1
TG (n = 652) 0.07 0.15** 0.04 0.37** 0.32** 1
CRP (n = 446) 0.01 0.07 0.06 0.23** 0.26** 0.26** 1
OPG (n = 446) 0.00 − 0.05 − 0.04 0.19** 0.13** 0.01 0.06 1
sTNFR1 (n = 441) 0.002 0.02 − 0.004 − 0.02 0.03 0.10* 0.14** 0.11* 1
IL-1RA (n = 446) − 0.01 − 0.04 0.04 − 0.02 − 0.02 − 0.02 − 0.02 0.10* 0.01
Table 3  Multivariate regression analysis
TC total cholesterol, LDL low-density lipoprotein, PANSS Positive and Negative Syndrome Scale, CDSS Calgary Depression Scale for Schizo-
phrenia, BMI body mass index, AP antipsychotics, CRP C-reactive protein, OPG osteoprotegerin
*p < 0.05, **p < 0.01
Serum TC levels Serum LDL levels
Standardized beta coefficients Standardized beta coefficients
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
PANSS positive 0.02 0.01 0.003 0.02 − 0.003 − 0.01
PANSS negative 0.05 0.05 0.04 0.08 0.05 0.05
CDSS 0.10* 0.13** 0.13** 0.10* 0.14** 0.14**
Age – 0.34** 0.30** – 0.28** 0.25**
Female gender – − 0.02 − 0.06 – − 0.13** − 0.16**
BMI – 0.12** 0.07 – 0.17** 0.11*
Daily smoking – 0.05 0.02 – 0.04 0.02
Duration of illness – − 0.06 − 0.05 – − 0.08 − 0.07
Schizophrenia 
group
– 0.07 0.06 – 0.07 0.07
AP inducing dys-
lipidemia
– 0.12** 0.09 – 0.10* 0.07
CRP – – 0.14** – – 0.16**
OPG – – 0.14** – – 0.11*
Adjusted R2 = 0.01
F(3, 442) = 2.10
p = 0.099
Adjusted R2 = 0.14
F(10, 435) = 8.04
p < 0.001
Adjusted R2 = 0.17
F(12, 433) = 8.42
p < 0.001
Adjusted R2 = 
0.01
F(3, 442) = 3.18
p = 0.024
Adjusted R2 = 0.14
F(10, 435) = 8.31
p < 0.001
Adjusted R2 = 0.17
F(12, 433) = 8.64
p < 0.001
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To the best of our knowledge, this is the first study that 
has investigated the role of depression in particular in asso-
ciation with dyslipidemia in patients with schizophrenia 
and other psychotic disorders. Dyslipidemia represents an 
important component of metabolic syndrome according to 
the National Cholesterol Education Program’s Adult Treat-
ment Panel III report (ATP III) [35]. Previous studies have 
addressed the significant association between depression 
and metabolic syndrome in general [36–38], and in schizo-
phrenia [39]. It is important to note that the relationship 
between depression and metabolic syndrome could be bidi-
rectional and reciprocal, as demonstrated by a meta-analysis 
conducted on both cohort and cross-sectional studies [40]. 
The same pattern of association was present with depression 
in relation to diabetes [41] and obesity [42]. This pattern 
could be extended to dyslipidemia, especially in psychotic 
disorders.
One of the major pathophysiological mechanisms pos-
sibly underlying the interplay between depression and 
dyslipidemia within the psychotic spectrum is the inflam-
matory pathway. Depression and schizophrenia have been 
firmly shown to be associated with elevated levels of sev-
eral inflammatory cytokines [15, 43]. In addition, patients 
with metabolic syndrome tend to have increased levels of 
cytokines [44], which may also be involved in associated 
depression [45]. The positive correlation between CRP, OPG 
and lipid levels in our sample supports the potential role of 
inflammatory pathway. The association between lipids and 
OPG has been demonstrated in many studies. For example, 
an animal study concluded that dyslipidemia resulted in 
increased OPG expression in mice [46]. While in humans, 
OPG levels were positively correlated with serum TC and 
LDL in a sample of 286 healthy women [47]. Moreover, it 
was reported that the use of statin therapy resulted in the 
reduction of OPG levels in patients with coronary artery 
disease [48].
It is worth noting that we did not find associations 
between levels of depression and any of the inflammatory 
markers included in this study. Similar results have been 
reported previously in a sub-sample of the present study, 
which found associations between sTNF-R1, IL-1Ra, OPG, 
IL-6 and severity of mood symptoms only in patients with 
bipolar disorders, but not in schizophrenia [49]. Although 
depression is associated with elevated levels of inflamma-
tory markers in many studies [15], depressive symptoms in 
schizophrenia may have a specific profile and a different 
pathophysiology compared to major depressive and other 
affective disorders [50]. This specific profile could be asso-
ciated with different immune profiles. Further, it is still not 
clear if increased level of cytokines represents a state or trait 
marker, especially since this study sample had depression 
severity means just around the cutoff score of CDSS.
Limitations of this study include the cross-sectional 
design and the inability to rule out other unknown confound-
ers that could have influenced our findings, in particular, that 
are related to lipid levels (e.g. dietary habits and exercise). It 
is worth to mention that we adjusted as much as possible for 
potential confounding factors such as medications, but this 
could not abolish the potential effect of other antipsychot-
ics on lipid metabolism by direct and indirect mechanisms, 
e.g. hyperprolactinemia and weight gain documented with 
first-generation antipsychotics [51]. In addition, the meas-
urements of lipid and inflammatory markers in peripheral 
blood may not necessarily reflect what is present in the brain. 
However, evidence from animal studies indicates potential 
communication across the blood–brain barrier. For example, 
synthesis of brain cholesterol has been reduced in guinea 
pigs under the effects of cholesterol-lowering statins [52]. 
Within the same context, studies on inflammatory cytokines 
have shown strong correlation between markers in peripheral 
blood and CSF [53]. Finally, we did not include the healthy 
controls in the association study since controls with mental 
symptoms were screened out.
In conclusion, findings from the current study tried to 
highlight the possible contributing role of depression in dys-
lipidemia within psychotic disorders together with the poten-
tial role of inflammatory markers in the pathophysiology of 
this important component of metabolic syndrome. Being an 
observational study, we cannot prove causality, but we can 
raise potential hypotheses for further investigation. Further 
studies are required to understand the interaction between 
inflammatory pathways and lipids on the one side, and their 
relation to the clinical profile of psychotic disorders on the 
other side, with particular emphasis on the role of depressive 
symptomatology. Exploring such complex mechanisms may 
be crucial for prevention and treatment of both dyslipidemia 
and depression within the psychotic spectrum.
Acknowledgements The authors would like to thank and acknowledge 
all the staff members in the NORMENT and KG Jebsen Centre for 
Psychosis Research who were involved in recruitment and assessments, 
and all participants in the study for their contribution.
Funding The research leading to these results has received funding 
from the European Union Seventh Framework Programme (FP7-PEO-
PLE-2013-COFUND) under Grant agreement no. 609020-Scientia Fel-
lows. In addition, the study was supported by grants from the Research 
Council of Norway to NORMENT CoE (Grant number 223273/F50, 
under the Centres of Excellence funding scheme), Stiftelsen Kristian 
Gerhard Jebsen (SKGJ-MED-008), and Regional Health Authority 
South-Eastern Norway: “Regional Research Network Psychotic Dis-
orders” (2014102).
Compliance with ethical standards 
Conflict of interest On behalf of all authors, the corresponding author 
states that there is no conflict of interest.
European Archives of Psychiatry and Clinical Neuroscience 
1 3
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Saari K, Jokelainen J, Veijola J, Koponen H, Jones PB, Savol-
ainen M, Jarvelin MR, Lauren L, Isohanni M, Lindeman S 
(2004) Serum lipids in schizophrenia and other functional psy-
choses: a general population northern Finland 1966 birth cohort 
survey. Acta Psychiatr Scand 110(4):279–285. https ://doi.org/1
0.1111/j.1600-0447.2004.00358 .x
 2. Brown S, Inskip H, Barraclough B (2000) Causes of the excess 
mortality of schizophrenia. Br J Psychiatry 177:212–217
 3. Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early 
mortality in schizophrenia. Ann Rev Clin Psychol 10:425–448. 
https ://doi.org/10.1146/annur ev-clinp sy-03281 3-15365 7
 4. Misiak B, Stanczykiewicz B, Laczmanski L, Frydecka D (2017) 
Lipid profile disturbances in antipsychotic-naive patients with 
first-episode non-affective psychosis: a systematic review 
and meta-analysis. Schizophr Res 190:18–27. https ://doi.
org/10.1016/j.schre s.2017.03.031
 5. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kend-
ler KS, O’Donovan MC, Rujescu D, Werge T, van de Bunt M, 
Morris AP, McCarthy MI, International Consortium for Blood 
Pressure G, Diabetes Genetics R, Meta-analysis C, Psychiatric 
Genomics Consortium Schizophrenia Working G, Roddey JC, 
McEvoy LK, Desikan RS, Dale AM (2013) Improved detec-
tion of common variants associated with schizophrenia by 
leveraging pleiotropy with cardiovascular-disease risk factors. 
Am J Human Genet 92 (2):197–209. https ://doi.org/10.1016/j.
ajhg.2013.01.001
 6. Solberg DK, Bentsen H, Refsum H, Andreassen OA (2016) 
Lipid profiles in schizophrenia associated with clinical traits: a 
five year follow-up study. BMC Psychiatry 16:299. https ://doi.
org/10.1186/s1288 8-016-1006-3
 7. Kahl KG, Greggersen W, Schweiger U, Cordes J, Balijepalli C, 
Lösch C, Moebus S (2012) Prevalence of the metabolic syndrome 
in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 
262(4):313–320. https ://doi.org/10.1007/s0040 6-011-0277-4
 8. Persons JE, Fiedorowicz JG (2016) Depression and serum 
low-density lipoprotein: a systematic review and meta-anal-
ysis. J Affect Disord 206:55–67. https ://doi.org/10.1016/j.
jad.2016.07.033
 9. Parekh A, Smeeth D, Milner Y, Thure S (2017) The role of lipid 
biomarkers in major depression. Healthcare (Basel Switz) 5 (1). 
https ://doi.org/10.3390/healt hcare 50100 05
 10. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, 
van Eijk JT, van Tilburg W (2001) Depression and cardiac mor-
tality: results from a community-based longitudinal study. Arch 
Gen Psychiatry 58(3):221–227
 11. Wysokinski A, Strzelecki D, Kloszewska I (2015) Levels of tri-
glycerides, cholesterol, LDL, HDL and glucose in patients with 
schizophrenia, unipolar depression and bipolar disorder. Dia-
betes Metab Syndrome 9(3):168–176. https ://doi.org/10.1016/j.
dsx.2015.04.004
 12. Gjerde PB, Dieset I, Simonsen C, Hoseth EZ, Iversen T, Lager-
berg TV, Lyngstad SH, Morch RH, Skrede S, Andreassen 
OA, Melle I, Steen VM (2017) Increase in serum HDL level 
is associated with less negative symptoms after one year of 
antipsychotic treatment in first-episode psychosis. Schizophr 
Res. https ://doi.org/10.1016/j.schre s.2017.10.042
 13. Mørch RH, Dieset I, Færden A, Hope S, Aas M, Nerhus M, 
Gardsjord ES, Joa I, Morken G, Agartz I, Aukrust P, Djurovic S, 
Melle I, Ueland T, Andreassen OA (2016) Inflammatory evidence 
for the psychosis continuum model. Psychoneuroendocrinology 
67:189–197. https ://doi.org/10.1016/j.psyne uen.2016.02.011
 14. Miller BJ, Goldsmith DR (2017) Towards an immunophenotype 
of schizophrenia: progress, potential mechanisms, and future 
directions. Neuropsychopharmacology 42(1):299–317. https ://
doi.org/10.1038/npp.2016.211
 15. Kohler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fer-
nandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Rai-
son CL, Miller BJ, Lanctot KL, Carvalho AF (2017) Peripheral 
cytokine and chemokine alterations in depression: a meta-analysis 
of 82 studies. Acta Psychiatr Scand 135(5):373–387. https ://doi.
org/10.1111/acps.12698 
 16. Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanadis 
C, Papavassiliou AG (2011) Inflammatory markers in hyperlipi-
demia: from experimental models to clinical practice. Curr Pharm 
Design 17(37):4132–4146
 17. Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, 
Maisano C, Jones L, Murrah NV, Vaccarino V (2008) Depres-
sive symptoms and metabolic syndrome: is inflammation the 
underlying link? Biol Psychiatry 64(10):896–900. https ://doi.
org/10.1016/j.biops ych.2008.05.019
 18. Rethorst CD, Bernstein I, Trivedi MH (2014) Inflammation, 
obesity, and metabolic syndrome in depression: analysis of the 
2009–2010 National Health and Nutrition Examination Survey 
(NHANES). J Clin Psychiatry 75(12):e1428-1432. https ://doi.
org/10.4088/JCP.14m09 009
 19. Nybo M, Rasmussen LM (2008) The capability of plasma osteo-
protegerin as a predictor of cardiovascular disease: a systematic 
literature review. Eur J Endocrinol 159(5):603–608. https ://doi.
org/10.1530/eje-08-0554
 20. Hope S, Melle I, Aukrust P, Agartz I, Lorentzen S, Steen NE, Dju-
rovic S, Ueland T, Andreassen OA (2010) Osteoprotegerin levels 
in patients with severe mental disorders. J Psychiatry Neurosci 
35(5):304–310. https ://doi.org/10.1503/jpn.09008 8
 21. Nerhus M, Berg AO, Kvitland LR, Dieset I, Hope S, Dahl SR, 
Weibell MA, Romm KL, Faerden A, Andreassen OA, Melle I 
(2016) Low vitamin D is associated with negative and depressive 
symptoms in psychotic disorders. Schizophr Res 178(1–3):44–49. 
https ://doi.org/10.1016/j.schre s.2016.08.024
 22. Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, 
Gardsjord E, Morch R, Agartz I, Melle I, Ueland T, Spigset O, 
Andreassen OA (2017) Serum levels of second-generation antip-
sychotics are associated with cognitive function in psychotic 
disorders. World J Biol Psychiatry 18(6):471–482. https ://doi.
org/10.1080/15622 975.2016.12454 41
 23. First MBSR., Gibbon M, Williams JBW (2002) Structured clini-
cal interview for DSM-IV-TR Axis I disorders, research version, 
patient edition (SCID-I/P) Biometrics Research. New York State 
Psychiatric Institute, New York
 24. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Nega-
tive Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 
13(2):261–276. https ://doi.org/10.1093/schbu l/13.2.261
 25. Addington D, Addington J, Schissel B (1990) A depression rating 
scale for schizophrenics. Schizophr Res 3(4):247–251. https ://doi.
org/10.1016/0920-9964(90)90005 -R
 26. Dieset I, Hope S, Ueland T, Bjella T, Agartz I, Melle I, Aukrust P, 
Røssberg J-I, Andreassen OA (2012) Cardiovascular risk factors 
during second generation antipsychotic treatment are associated 
with increased C-reactive protein. Schizophr Res 140(1):169–174. 
https ://doi.org/10.1016/j.schre s.2012.06.040
 European Archives of Psychiatry and Clinical Neuroscience
1 3
 27. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, 
Agartz I, Aukrust P, Andreassen OA (2013) Interleukin 1 receptor 
antagonist and soluble tumor necrosis factor receptor 1 are associ-
ated with general severity and psychotic symptoms in schizophre-
nia and bipolar disorder. Schizophr Res 145(1):36–42. https ://doi.
org/10.1016/j.schre s.2012.12.023
 28. Goncalves P, Araujo JR, Martel F (2015) Antipsychotics-induced 
metabolic alterations: focus on adipose tissue and molecular 
mechanisms. Eur Neuropsychopharmacol 25(1):1–16. https ://
doi.org/10.1016/j.euron euro.2014.11.008
 29. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, 
Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic 
syndrome and its components in people with schizophrenia and 
related psychotic disorders, bipolar disorder and major depressive 
disorder: a systematic review and meta-analysis. World Psychiatry 
14(3):339–347. https ://doi.org/10.1002/wps.20252 
 30. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2011) 
Metabolic and cardiovascular adverse effects associated with 
antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126. https ://
doi.org/10.1038/nrend o.2011.156
 31. Addington D, Addington J, Maticka-Tyndale E (1994) Specificity 
of the Calgary Depression Scale for schizophrenics. Schizophr 
Res 11(3):239–244
 32. Sands JR, Harrow M (1999) Depression during the longitudinal 
course of schizophrenia. Schizophr Bull 25(1):157–171
 33. Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, 
Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E 
(2007) Subsyndromal depressive symptoms in middle-aged and 
older persons with schizophrenia. Am J Geriatric Psychiatry 
15(12):1005–1014. https ://doi.org/10.1097/JGP.0b013 e3180 a725e 
c
 34. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P (2003) 
Depression and subjective quality of life in chronic phase schizo-
phrenic patients. Acta Psychiatr Scand 108(4):297–303
 35. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C 
(2004) Definition of metabolic syndrome: report of the National 
Heart, Lung, and Blood Institute/American Heart Association 
conference on scientific issues related to definition. Arterioscler 
Thromb Vasc Biol 24 (2):e13-18. https ://doi.org/10.1161/01.
atv.00001 11245 .75752 .c6
 36. Akbaraly TN, Kivimaki M, Brunner EJ, Chandola T, Marmot MG, 
Singh-Manoux A, Ferrie JE (2009) Association between meta-
bolic syndrome and depressive symptoms in middle-aged adults: 
results from the Whitehall II study. Diabetes care 32(3):499–504. 
https ://doi.org/10.2337/dc08-1358
 37. Skilton MR, Moulin P, Terra JL, Bonnet F (2007) Associations 
between anxiety, depression, and the metabolic syndrome. Biol 
Psychiatry 62(11):1251–1257. https ://doi.org/10.1016/j.biops 
ych.2007.01.012
 38. Viinamaki H, Heiskanen T, Lehto SM, Niskanen L, Koivu-
maa-Honkanen H, Tolmunen T, Honkalampi K, Saharinen T, 
Haatainen K, Hintikka J (2009) Association of depressive symp-
toms and metabolic syndrome in men. Acta Psychiatr Scand 
120(1):23–29. https ://doi.org/10.1111/j.1600-0447.2008.01333 .x
 39. Suttajit S, Pilakanta S (2013) Prevalence of metabolic syndrome 
and its association with depression in patients with schizophre-
nia. Neuropsychiatr Dis Treat 9:941–946. https ://doi.org/10.2147/
NDT.S4745 0
 40. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, 
Hu FB (2012) Bidirectional association between depression and 
metabolic syndrome: a systematic review and meta-analysis of 
epidemiological studies. Diabetes Care 35(5):1171–1180. https 
://doi.org/10.2337/dc11-2055
 41. Mezuk B, Eaton WW, Albrecht S, Golden SH (2008) Depression 
and type 2 diabetes over the lifespan: a meta-analysis. Diabetes 
Care 31(12):2383–2390. https ://doi.org/10.2337/dc08-0985
 42. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx 
BW, Zitman FG (2010) Overweight, obesity, and depression: a 
systematic review and meta-analysis of longitudinal studies. Arch 
Gen Psychiatry 67(3):220–229. https ://doi.org/10.1001/archg 
enpsy chiat ry.2010.2
 43. Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine 
function in medication-naive first episode psychosis: a systematic 
review and meta-analysis. Schizophr Res 155(1–3):101–108. https 
://doi.org/10.1016/j.schre s.2014.03.005
 44. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syn-
drome. Lancet 365(9468):1415–1428. https ://doi.org/10.1016/
s0140 -6736(05)66378 -7
 45. Martinac M, Pehar D, Karlovic D, Babic D, Marcinko D, Jakovlje-
vic M (2014) Metabolic syndrome, activity of the hypothalamic-
pituitary-adrenal axis and inflammatory mediators in depressive 
disorder. Acta Clin Croat 53(1):55–71
 46. Toffoli B, Fabris B, Bartelloni G, Bossi F, Bernardi S (2016) 
Dyslipidemia and diabetes increase the OPG/TRAIL ratio in the 
cardiovascular system. Mediat Inflamm 2016:6529728. https ://
doi.org/10.1155/2016/65297 28
 47. Oh ES, Rhee EJ, Oh KW, Lee WY, Baek KH, Yoon KH, Kang MI, 
Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW (2005) Circulat-
ing osteoprotegerin levels are associated with age, waist-to-hip 
ratio, serum total cholesterol, and low-density lipoprotein cho-
lesterol levels in healthy Korean women. Metabolism Clin Exp 
54(1):49–54. https ://doi.org/10.1016/j.metab ol.2004.08.005
 48. Kadoglou NP, Kottas G, Lampropoulos S, Vitta I, Liapis CD 
(2014) Serum levels of fetuin-A, osteoprotegerin and osteopontin 
in patients with coronary artery disease: effects of statin (HMG-
CoA-reductase inhibitor) therapy. Clin Drug Investig 34(3):165–
171. https ://doi.org/10.1007/s4026 1-013-0157-y
 49. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, Aukrust 
P, Andreassen OA (2011) Affective symptoms are associated with 
markers of inflammation and immune activation in bipolar dis-
orders but not in schizophrenia. J Psychiatric Res 45(12):1608–
1616. https ://doi.org/10.1016/j.jpsyc hires .2011.08.003
 50. Siris SG (2000) Depression in schizophrenia: perspective in 
the era of “Atypical” antipsychotic agents. Am J Psychiatry 
157(9):1379–1389. https ://doi.org/10.1176/appi.ajp.157.9.1379
 51. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, 
Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf 
MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy 
and tolerability of 15 antipsychotic drugs in schizophrenia: a 
multiple-treatments meta-analysis. Lancet 382(9896):951–962. 
https ://doi.org/10.1016/s0140 -6736(13)60733 -3
 52. Lutjohann D, Stroick M, Bertsch T, Kuhl S, Lindenthal B, Thelen 
K, Andersson U, Bjorkhem I, Bergmann Kv K, Fassbender K 
(2004) High doses of simvastatin, pravastatin, and cholesterol 
reduce brain cholesterol synthesis in guinea pigs. Steroids 
69(6):431–438. https ://doi.org/10.1016/j.stero ids.2004.03.012
 53. Tomasik J, Rahmoune H, Guest PC, Bahn S (2016) Neuroimmune 
biomarkers in schizophrenia. Schizophr Res 176(1):3–13. https ://
doi.org/10.1016/j.schre s.2014.07.025
